Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Krystal Biotech Inc. | KB803 - (IOLITE) | Corneal abrasions in Dystrophic Epidermolysis Bullosa (DEB) patients | Phase 3 | Ongoing | topical | Opthalmic |
| Krystal Biotech Inc. | KB803 - (IOLITE) | Corneal abrasions in Dystrophic Epidermolysis Bullosa (DEB) patients | Phase 3 | Ongoing | topical | Opthalmic |
| Krystal Biotech Inc. | KB803 (B-VEC formulated as an eyedrop) - (IOLITE) | Dystrophic epidermolysis bullosa (DEB) | Phase 3 | Enrollment Initiation | Topical | Genetic Disorder |
| Krystal Biotech Inc. | KB111 | Hailey-Hailey disease (HHD) | Phase 2 | Ongoing | Topical | #N/A |
| Krystal Biotech Inc. | KB301 - (PEARL-1) | Wrinkles and acne scars | Phase 2 | Trial Planned | Intracutaneous | N/A |
| Kura Oncology Inc. | Ziftomenib - (KOMET-017-IC) | Newly diagnosed NPM1-m and/or KMT2A-r AML | Phase 3 | Trial Planned | Intravenous | Oncology |
| Kura Oncology Inc. | Tipifarnib | Head and neck squamous cell carcinomas (HNSCC) with HRAS Mutations | Phase 2 | Trial Completed | Oral | Oncology |
| Kymera Therapeutics Inc. | KT-621 - (BREADTH) | Asthma | Phase 2b | Ongoing | oral | Respiratory |
